Current Report Filing (8-k)
June 04 2018 - 7:17AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 4, 2018
Cocrystal
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38418
|
|
35-2528215
|
(State
or other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
1860
Montreal Rd, Tucker, GA
|
|
30084
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (678) 892-8800
(Former
name or former address, if changed since last report.):
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01 Regulation FD Disclosure
Senior executives of Cocrystal
Pharma, Inc. (the “Company”) will be delivering several presentations. The Company’s investor
presentation has been updated and is being furnished as Exhibit 99.1 hereto and is hereby incorporated by
reference.
The
information in this Current Report on Form 8-K (including exhibits hereto) shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the
liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the
Securities Act of 1933, as amended, or the Exchange Act.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Cocrystal Pharma, Inc.
|
|
|
|
Date:
June 4, 2018
|
By:
|
/s/
James Martin
|
|
Name:
|
James
Martin
|
|
Title:
|
Chief
Financial Officer
|
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2024 to May 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From May 2023 to May 2024